JY
TRDA icon

Jeff Yass’s Entrada Therapeutics TRDA Stock Holding History

Jeff Yass’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,100
Closed -$292K – 14550
2026
Q1 		$292K Buy
23,100
+900
+4% +$10.3K ﹤0.01% 10923
2025
Q4 		$228K Buy
22,200
+8,500
+62% +$71.6K ﹤0.01% 10575
2025
Q3 		$79.5K Sell
13,700
-2,000
-13% -$11.7K ﹤0.01% 11683
2025
Q2 		$106K Buy
+15,700
New +$126K ﹤0.01% 11767
2025
Q1 		– Sell
-31,700
Closed -$548K – 13473
2024
Q4 		$548K Buy
31,700
+2,000
+7% +$36.2K ﹤0.01% 8445
2024
Q3 		$475K Buy
+29,700
New +$468K ﹤0.01% 8581

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Jeff Yass's TRDA Position: Q2 2026 in Review

Jeff Yass sold out of Entrada Therapeutics (TRDA) in Q2 2026, closing a stake of 20,315 shares — an estimated $256K sold.

Jeff Yass first reported a position in TRDA in Q4 2022 and held it in 8 quarters. The position peaked at $2.85M in Q1 2023. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Jeff Yass reported no remaining Entrada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 20,315 Entrada Therapeutics shares in Q2 2026, an estimated $256K.
  • Jeff Yass first reported a position in Entrada Therapeutics in Q4 2022 and held it in 8 quarters.
  • Jeff Yass's Entrada Therapeutics position peaked at $2.85M in Q1 2023.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.